Observational studyJournal of paediatrics and child health2026
The Impact of Limited-Eligibility Nirsevimab on Paediatric Respiratory Syncytial Virus (RSV) Infection and Hospitalisations in the Australian Capital Territory: An Observational Cohort Study.
Observational study in Journal of paediatrics and child health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimTo assess changes in Respiratory Syncytial Virus (RSV) epidemiology and hospitalisations following implementation of a limited-eligibility nirsevimab program.
methodsThis observational cohort study included all infants aged < 2 years residing in our jurisdiction with laboratory-confirmed RSV and/or receipt of an RSV monoclonal antibody between April 2022 and March 2025. Cases were followed for emergency department (ED) presentations and hospital admissions. Primary outcomes were RSV incidence, ED presentation, and hospitalisation rates.
resultsWe identified 2355 RSV cases, with 1625 infants presenting to ED and 701 hospitalised. Among 308 infants receiving nirsevimab, the most common indication was prematurity; 2.4% experienced breakthrough RSV infection. RSV incidence increased post-nirsevimab (April 2024-March 2025: 89.06/1000 infant-years) compared with the pre-nirsevimab period (April 2022-March 2024: 67.99/1000 infant-years), consistent with local and national trends. Characteristics of hospitalised infants changed in the post-nirsevimab period: age increased (from 9.4 to 10.7 months, p = 0.019), the proportion aged < 3 months decreased (from 27.6% to 19.7%, p = 0.013) and prematurity prevalence nearly halved (from 13.3% to 7.3%, p = 0.041). Clinical characteristics also changed, with an 8-h reduction in length of stay (p = 0.010), and a one fifth reduction in the need for respiratory support (p < 0.001). No significant differences were observed for Aboriginal and Torres Strait Islander infants.
conclusionsHospitalisations among infants at greatest risk for severe RSV disease reduced following introduction of the limited-eligibility nirsevimab program. However, Aboriginal and Torres Strait Islander infants remained over-represented in hospital admissions and under-served by the program in its first year, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.